Furoscix, an innovative subcutaneous furosemide injection by scPharmaceuticals, has received FDA approval for treating edema associated with chronic kidney disease (CKD), including nephrotic syndrome. Originally approved for chronic heart failure, Furoscix can now help CKD patients manage edema at home, reducing hospital visits and enhancing quality of life. Edema in CKD results from excess fluid retention, posing risks such as cardiovascular complications, pulmonary edema, and accelerated kidney damage. By delivering precise doses via an easy-to-use, pre-filled injection device, Furoscix allows effective at-home fluid management, helping patients maintain better cardiovascular health and slowing CKD progression.

Eli Lilly’s OmvohⓇ (mirikizumab-mrkz) has received FDA approval for a new indication—moderate to severe Crohn’s disease (CD) in adults. Learn how this expands treatment options for IBD, its clinical significance, and what it means for the pharmaceutical industry.

In this post, we’ll break down why pushing through stress isn’t the answer—and how small, intentional pauses can actually make you more productive. You’ll learn how to create your own Pause and Power-Up Menu, a personalized toolkit of quick resets designed to help you reduce stress, regain focus, and work smarter, not harder.

In this post, we’ll walk you through five vital signs of a healthy career and provide actionable tips to help you evaluate where you stand. Let’s ensure you’re on track for growth, satisfaction, and success in 2025.